Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABOSTO:MCAP -0.54%86 Debt-to-EBITDA is 0.77 as of Jun. 2026, which is 48% below its 10-year median of 1.49. GuruFocus rates OSTO:MCAP with a GF Score™ of 86/100 and a GF Value™ of kr567.64 (Fairly Valued). Among 469 Medical Devices & Instruments companies, MedCap AB ranks better than 61.41% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for MedCap AB's Debt-to-EBITDA or its related term are showing as below:
OSTO:MCAP'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.76 Med: 1.49 Max: 4.47
Current: 0.85
During the past 13 years, the highest Debt-to-EBITDA Ratio of MedCap AB was 4.47. The lowest was 0.76. And the median was 1.49.
OSTO:MCAP's Debt-to-EBITDA is ranked better than 61.41% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs OSTO:MCAP: 0.85
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
MedCap AB Debt-to-EBITDA Related Terms
MedCap AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for MedCap AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MCAP vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, MedCap AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MedCap AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
MedCap AB (OSTO:MCAP) has a Debt-to-EBITDA of 0.77 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MedCap AB. This is 48% below median its historical median of 1.49. Over the past decade, MedCap AB's Debt-to-EBITDA has ranged from 0.76 to 4.47. According to the industry distribution chart, MedCap AB ranks #181 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 38.6%.
Is MedCap AB's Debt-to-EBITDA too high?
MedCap AB's current Debt-to-EBITDA of 0.77 is 48% below median its 10-year median of 1.49. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 4.47. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. MedCap AB's value of 0.77 is 51.9% below this industry median. Based on the distribution chart, MedCap AB ranks #181 out of 469 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MedCap AB has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #181 out of 469 companies for Debt-to-EBITDA. This puts MedCap AB in the upper half of its industry. The industry median Debt-to-EBITDA is 1.60. MedCap AB's value of 0.77 is 51.9% below this benchmark. Historically, MedCap AB's own Debt-to-EBITDA has ranged from 0.76 to 4.47 over the past decade. While the company's 10-year median is 1.49 vs. the industry median of 1.60, MedCap AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current Debt-to-EBITDA of 0.77 is 51.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MedCap AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current Debt-to-EBITDA is 0.77, which is 48% below median its own 10-year median of 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr567.64, compared to a current price of kr548.50 — trading 3.4% below its estimated fair value. The current Debt-to-EBITDA is 0.77, which is 48% below median its 10-year median of 1.49 and 51.9% below the Medical Devices & Instruments industry median of 1.60. MedCap AB's overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current Debt-to-EBITDA is 0.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (OSTO:MCAP) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of kr548.50 is trading 3.4% below its estimated GF Value™ of kr567.64.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for OSTO:MCAP:
Debt-to-EBITDA: 0.77 (48% below median its 10-year median of 1.49)
GF Value™: kr567.64 vs. price of kr548.50 (3.4% below fair value)
Industry Position: 51.9% below the Medical Devices & Instruments median (#181 of 469)
No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
86GF Score
Get the complete analysis for OSTO:MCAP
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MCAP has been successfully added to your 
